- Joined
- Apr 16, 2004
- Messages
- 4,658
- Reaction score
- 5,066
Interesting news reports out today regarding new recommendations from a consensus panel of medical oncologists on behalf of ASCO.
I really have to give ASCO credit for these bold and far-seeing recommendations. These tests/interventions have not proven to be beneficial through any good evidence-based approach.
For every patient story we hear about, "I had Stage I breast cancer and a PET/CT showed bone mets!," there are dozens of stories of patients being harmed by biopsying benign lesions which we don't hear about in the media.
patients who have been successfully treated for breast cancer and have no symptoms of cancer not undergo CT, PET, other imaging, or bone scans to check for a recurrence or spread of the disease, known as metastasis.
ASCO recommends against routine use of four other procedures: chemotherapy for patients with advanced cancers who are unlikely to benefit; advanced imaging technologies such as CT and PET or bone scans to determine the precise stage of both early breast and prostate cancers at low risk for metastasis; and drugs to stimulate white blood cell production in patients receiving chemotherapy if they have a risk of febrile neutropenia, an often-fatal condition marked by fever and abnormally low numbers of certain white blood cells.
I really have to give ASCO credit for these bold and far-seeing recommendations. These tests/interventions have not proven to be beneficial through any good evidence-based approach.
For every patient story we hear about, "I had Stage I breast cancer and a PET/CT showed bone mets!," there are dozens of stories of patients being harmed by biopsying benign lesions which we don't hear about in the media.